Update on emerging treatments for migraine /

Detalles Bibliográficos
Clasificación:Libro Electrónico
Otros Autores: Wang, Shuu-Jiun (Editor ), Lau, Chi leong (Editor )
Formato: Electrónico eBook
Idioma:Inglés
Publicado: Amsterdam : Elsevier, 2020.
Edición:First edition.
Colección:Progress in brain research ; 255.
Temas:
Migraine > Treatment.
Migraine Disorders > therapy
Migraine > Traitement.
Migraine > Treatment
Internet Resources.
Index not Present.
Acceso en línea:Texto completo
Tabla de Contenidos:
  • Intro
  • Update on Emerging Treatments for Migraine
  • Copyright
  • Contributors
  • Contents
  • Preface
  • Chapter 1: Update in migraine preventive treatment
  • Abstract
  • Keywords
  • 1. Introduction
  • 2. Preventive medications for migraine
  • 2.1. Beta-blockers
  • 2.2. Antiepileptic drugs
  • 2.3. Calcium channel blockers
  • 2.4. Antidepressants
  • 2.5. Non-steroid anti-inflammatory drugs (NSAIDs)
  • 2.6. Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)
  • 2.7. Miscellaneous
  • 3. Preventive medications for chronic migraine
  • 3.1. OnabotulinumtoxinA
  • 3.2. Topiramate
  • 4. Calcitonin gene-related peptide monoclonal antibodies
  • 4.1. Erenumab
  • 4.2. Galcanezumab
  • 4.3. Fremanezumab
  • 4.4. Eptinezumab
  • 5. Special considerations
  • 5.1. Menstrual-related migraine
  • 5.2. Pregnancy and breastfeeding
  • 5.3. Children and adolescents
  • 6. Conclusion
  • References
  • Chapter 2: Therapeutic implications of cortical spreading depression models in migraine
  • Abstract
  • Keyword
  • 1. Migraine
  • 2. Cortical spreading depression
  • 3. Basics on in vivo experimental models of CSD
  • 4. Consequences of CSD
  • 4.1. Trigeminovascular activation
  • 4.2. Cortical inflammation
  • 4.3. Disruption of blood-brain barrier and impaired glymphatic flow
  • 5. Migraine modulators affect CSD susceptibility
  • 5.1. Genetic factors
  • 5.2. Sex and age
  • 5.3. Stress, sleep deprivation and hypoglycemia
  • 6. CSD inhibition reflecting clinical responsiveness
  • 7. CSD inhibitors that inhibit migraine aura but not headache
  • 7.1. Ketamine
  • 7.2. Lamotrigine
  • 7.3. Tonabersat
  • 8. Novel targets for migraine therapeutics
  • 8.1. Calcitonin gene-related peptide
  • 8.2. Ion channels
  • 8.2.1. Pannexin-1 channels and P2X7 receptors
  • 8.2.2. Acid-sensing ion channels (ASICs)
  • 8.2.3. Transient receptor potential (TRP) channels
  • 8.2.4. TWIK-related spinal cord potassium channel (TRESK)
  • 8.3. Insulin-like growth factor-1 (IGF-1)
  • 8.4. Neuromodulation
  • 8.4.1. Vagus nerve stimulation
  • 8.4.2. Transcranial magnetic stimulation
  • 8.4.3. Transcranial direct current stimulation
  • 9. Future directions and potentials for CSD models
  • 10. Conclusion
  • Funding
  • References
  • Chapter 3: Electrophysiological basis for antiepileptic drugs in migraine prevention
  • Abstract
  • Keywords
  • 1. Introduction
  • 2. Basic concepts of electrophysiological studies in migraine
  • 3. The visual cortex
  • 3.1. Steady-state visual evoked potential (SSVEP)
  • 3.2. Pattern reversal visual evoked potential (PRVEP)
  • 3.3. Phosphene induced by transcranial magnetic stimulation
  • 3.4. Magnetic suppression of perceptual accuracy (MSPA)
  • 4. The somatosensory cortex
  • 4.1. Standard (broad-band) somatosensory evoked potential
  • 4.2. High-frequency oscillations of the somatosensory evoked potential
  • 5. The motor cortex
  • 5.1. Motor threshold (MTh) and motor evoked potentials (MEPs)
  • 5.2. Silent period (SP)

Ejemplares similares